Amir Gholami, MD
Infectious Disease · Omaha, NENPI 1942236807
Payments from drug & device makers
Across 489 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- AbbVie$1K
- Merck$1K
- Melinta Therapeutics, LLC$716
- Astellas Pharma US Inc$534
- plus $5K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 67 | $2,015 |
| Gilead | 58 | $1,447 |
| AbbVie(2 entities) | 75 | $1,379 |
| Merck | 56 | $1,164 |
| Melinta Therapeutics, LLC | 32 | $716 |
| Astellas Pharma US Inc | 15 | $534 |
| Aimmune Therapeutics, Inc. | 10 | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $492 |
| Paratek Pharmaceuticals, Inc. | 16 | $476 |
| Insmed, Inc. | 20 | $431 |
| Pfizer | 18 | $346 |
| CSL Behring | 11 | $341 |
| Ferring Pharmaceuticals Inc. | 12 | $340 |
| Johnson & Johnson(2 entities) | 16 | $327 |
| Grifols USA, LLC | 14 | $326 |
| Amgen(2 entities) | 8 | $274 |
| Shionogi Inc | 7 | $242 |
| Janssen Products, LP | 2 | $159 |
| Hospira, Inc. | 8 | $131 |
| Octapharma USA, Inc. | 4 | $124 |
| Nestle Healthcare Nutrition Inc. | 2 | $92 |
| Pharming Healthcare, Inc. | 2 | $43 |
| Smith+Nephew | 3 | $42 |
| Bio Products Laboratory USA, Inc. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $40 |
| GC Biopharma USA, Inc. | 2 | $39 |
| Dynavax Technologies Corporation | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Shire North American Group Inc | 1 | $23 |
| AstraZeneca | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $11 |
How this compares
$12,200 in reported general payments places this provider in the 70th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Omaha
- Diana FlorescuOmaha$2.8M
- Howard GendelmanOmaha$2.1M
- Natalia Castillo AlmeidaOmaha$1.2M
- Sara BaresOmaha$611K
- Rudolf KotulaOmaha$520K
- Susan SwindellsOmaha$493K
- Richard StarlinOmaha$394K
- Alison FreifeldOmaha$300K
- Andrea ZimmerOmaha$196K
- Trevor VanschooneveldOmaha$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.